US FDA Struggling With Long-Term Follow-Up Requirements For Gene Therapies

OTP Director Nicole Verdun acknowledged the agency may need help to determine how to ensure 15 years of patient follow-up is completed despite physician retirements, company closures and other issues that could impact the post-market commitments for gene therapies.

long-term
Many data collection hurdles could arise in the 15-year follow-up period for gene therapy patients. • Source: Shutterstock

Ensuring that long-term follow-up agreements for gene therapy patients remain unencumbered despite economic or personnel changes is proving to be a question that may require multi-stakeholder creativity to answer, US Food and Drug Administration officials acknowledged.

Because gene therapies still are new and their long-term effects unknown, the agency wants sponsors to track recipients for up...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies